Gastrointestinal Cancer | Specialty

Novel Metabolic Therapy Demonstrates Activity in Metastatic Pancreatic Cancer

February 8th 2019

SM-88, a novel compound that attacks oncogenic metabolic pathways, is under development for patients with metastatic pancreatic cancer and other solid tumors, raising the potential for a tumor-agnostic therapy.

Overcoming Challenges in the Management of mCRC

February 8th 2019

Later-Line Treatment for mCRC: Regorafenib or TAS-102?

February 8th 2019

mCRC: Stratifying Patients to Appropriate Therapy

February 8th 2019

Improving Molecular Understandings of mCRC

February 8th 2019

Metastatic Colorectal Cancer: Frontline Treatment Paradigm

February 8th 2019

Dr. Mody Highlights Treatment Advances in HCC

February 8th 2019

Kabir Mody, assistant professor of medicine, consultant, Division of Hematology/Oncology, Mayo Clinic, highlights the recent treatment advances for patients with hepatocellular carcinoma.

Future of CRC Rests in Greater Genomic Understanding

February 7th 2019

Marwan Fakih, MD, discusses recent trials in colorectal cancer and highlights other ongoing research in the field.

Dr. Li on Preoperative Immunotherapy in Hepatocellular Carcinoma

February 6th 2019

Daneng Li, MD, an assistant clinical professor in the Department of Medical Oncology and Therapeutics Research, and a medical oncologist at City of Hope, discusses an ongoing study of preoperative immunotherapy in patients with hepatocellular carcinoma (HCC).

Dr. Kasi on the Application of Pharmacogenomics in CRC

February 5th 2019

Pashtoon M. Kasi, MD, MBBS, MS, assistant professor of oncology and senior associate consultant in the Division of Hematology/Oncology at Mayo Clinic, discusses the application of pharmacogenomics in colorectal cancer (CRC).

Targeted Therapies, Triplet Regimens Becoming Focus in Biliary Tract Cancers

February 5th 2019

Rachna T. Shroff, MD, MS, highlighted the ongoing research efforts in biliary tract cancers, specifically with cholangiocarcinoma treatment.

Online Tool Estimates the Risk for Lynch Syndrome

February 5th 2019

Because specific risk-reducing interventions may be available, it is important to identify individuals with germline variants in cancer susceptibility genes.

Further Evidence Needed Supporting Clinical Utility of Liquid Biopsies in GI Cancers

February 5th 2019

John Strickler, MD, discusses how liquid biopsies are being used to help guide treatment decisions for patients with GI cancers and shed light on other research efforts that are being made to improve outcomes.

Chung Captures Key Advances Across Pancreatic Cancer Paradigm

February 4th 2019

Vincent Chung, MD, discusses the therapeutic landscape of early-stage and advanced pancreatic cancer.

Expert Discusses CRC Developments, Importance of Molecular Profiling

February 4th 2019

Pashtoon M. Kasi, MD, MBBS, MS, provides an overview of the potential for liquid biopsies in CRC and advances being made in the treatment landscape.

Expert Highlights Ongoing Research Efforts in HCC, NETs

February 1st 2019

Daneng Li, MD, shed light on some of the currently available regimens and ongoing research efforts being conducted in hepatocellular carcinoma and neuroendocrine tumors.

Overcoming Acquired Resistance Mechanisms in BRAF+ mCRC

January 31st 2019

First-Line Triplet in BRAF+ mCRC

January 31st 2019

Real-World Management of Patients with BRAF-V600E mCRC

January 31st 2019

CRC Safety Lead-in: ASCO GI 2019 Updates

January 31st 2019